Isolation and characterization of a low molecular weight growth-promoting factor from human plasma

Heulin, M. G.; Rajoelina, J.; Artur, Michèle; Geschier, C.; Straczek, J.; Lasbennes, A; Belleville, F.; Nabet, P

doi:10.1016/0024-3205(87)90152-4

Cited by 7 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we showed that both the DRC3f-containing serum samples and the filtered DRC3f-containing serum samples (containing only molecules with molecular weights of lower than ϳ3 kd) enhanced the proliferation of HMVECs (Figure 4). These results suggest that DRC3f is one of the low molecular weight growth factors in sera (22,35). However, morphologic abnormalities in the vessels, defective angiogenesis, and apoptosis instead of proliferation of endothelial cells are common features of the microvasculature in SSc.…”

Section: Discussionmentioning

confidence: 83%

Comprehensive investigation of disease‐specific short peptides in sera from patients with systemic sclerosis: Complement C3f‐des‐arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells

Xiang¹,

Matsui²,

Matsuo³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To identify pathogenic and/or diseasespecific short peptides in sera from patients with systemic sclerosis (SSc).Methods. Serum samples from 40 patients with SSc, 30 patients with systemic lupus erythematosus, 21 patients with rheumatoid arthritis, 30 patients with osteoarthritis, and 26 healthy donors were tested. Short peptides with molecular weights of smaller than ϳ3 kd, purified from the sera by magnetic bead-based hydrophobic interaction chromatography 18, were detected and their amino acid sequences determined using matrix-assisted laser desorption ionization-time-offlight mass spectrometry. Effects of the identified peptides on fibroblasts and microvascular endothelial cells were tested using synthesized peptides and sera containing the peptides.

show abstract

Section: Discussionmentioning

confidence: 83%

Comprehensive investigation of disease‐specific short peptides in sera from patients with systemic sclerosis: Complement C3f‐des‐arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells

Xiang¹,

Matsui²,

Matsuo³

et al. 2007

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…Besides these peptides, characterized at the at the primary sequence level, interesting IGF-like peptides or fractions were described, amongst others, by Liberti [95], Cockerill, Cornell, Herington and Kuffer [96], Posner [97], Moses [61], Minuto and Barreca [98], Blum [99], Gowan [100], Heulin [101], De Ceuninck [102]and their respective co-workers, which represented important leads. Not all have received sufficient follow-up.…”

Section: Sulphation Factor-somatomedin Is Insulin-likementioning

confidence: 99%

A Personal View on the Early History of the Insulin-Like Growth Factors

Brande¹

1999

Horm Res Paediatr

View full text Add to dashboard Cite

Salmon and Daughaday, when trying to set up an in vitro assay for Growth Hormone (GH), failed to obtain a direct effect on sulphate uptake in cartilage of hypophysectomized (hypox) rats. They recognised that this was not the consequence of poor methodology or materials, but an encrypted message from the examined system. They decided to turn around and to try and decipher it. Treatment with GH appeared to render hypox rat serum active in stimulating sulphation in hypox rat cartilage. They proposed that GH induced an intermediary substance, responsible for this biological effect: sulphation factor (SF), later renamed to Somatomedin(s) (SM). This hypothesis met with great criticism and very few took on to study this hypothetical substance. Besides disbelief, slow progress was also due to initial lack of a practical assay and to the failure to find a tissue with enriched concentration from which to extract the activity. From experimental evidence, the concept gradually evolved that SF/SM was insulin-like and might be identical to NSILA (non-suppressible insulin-like activity). This again generated controversy. This characteristic was too far away from the known effects of GH to be readily acceptable as a physiological phenomenon. The subsequent recognition of the distinct characteristics of the receptors for SM/NSILA and insulin, the discovery of the SM/NSILA binding proteins and, much later, a beginning understanding of their interactions, modifications and breakdown, have gradually resolved this apparent contradiction. When the sequence of two NSILA molecules became known, they were named IGF-I and -II. Structural similarity with proinsulin and identity of IGF-I with SM-C and -A were established and it was found that Multiplication Stimulating Activity (MSA), a growth factor isolated from fetal calf serum and subsequently from conditioned media of a rat liver cell line, was the rat equivalent of IGF-II. Structure-function relations could be studied, a quest which is not yet brought to an end. Meanwhile, the endocrine profile of SF/SM had gradually emerged by measuring plasma levels with bioassays. The main determinants were found to be age, body size, GH and the nutritional state. Later, radioimmunoassays were developed, enabling consolidation and detailing of these early observations, and allowing explorations at the tissue level. As another aspect of the endocrine paradigm, in vivo effects of IGFs were studied. The initial demonstration of an effect of crude preparations on longitudinal growth in experimental animals raised heavy scepticism, since the effect might have been an artefact caused by contaminants. It took confirmation with highly purified preparations and biosynthetic IGF-I to ease this concern. Still, not until recent years it was demonstrated, by knocking out the genes, that a true physiological and not a pharmacological effect had been induced previously.When it was found that most tissues produce SMs and are sensitive to their actions, the concept emerged that IGFs may have para- and autocrine fu...

show abstract

Purification from Human Plasma of a Hexapeptide That Potentiates the Sulfation and Mitogenic Activities of Insulin-like Growth Factors

Dousset¹,

Straczek²,

Maachi³

et al. 1998

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Isolation and characterization of a low molecular weight growth-promoting factor from human plasma

Cited by 7 publications

References 12 publications

Comprehensive investigation of disease‐specific short peptides in sera from patients with systemic sclerosis: Complement C3f‐des‐arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells

Comprehensive investigation of disease‐specific short peptides in sera from patients with systemic sclerosis: Complement C3f‐des‐arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells

A Personal View on the Early History of the Insulin-Like Growth Factors

Purification from Human Plasma of a Hexapeptide That Potentiates the Sulfation and Mitogenic Activities of Insulin-like Growth Factors

Contact Info

Product

Resources

About